Compare
Celularity Inc vs Cue Biopharma, Inc. vs Alumis Inc. vs Foghorn Therapeutics Inc.
| Latest fiscal year | Celularity Inc CELU | Cue Biopharma, Inc. CUE | Alumis Inc. ALMS | Foghorn Therapeutics Inc. FHTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $26.55M | $27.47M | $24.05M | $30.91M |
| Revenue growth (YoY) | -51.0% | +195.7% | n/a | +36.8% |
| Gross margin | 24.4% (computed) | n/a | n/a | n/a |
| Operating margin | -230.9% | -96.7% | n/m | -279.5% |
| Net margin | -345.4% | -96.9% | n/m | -240.3% |
| Net income | -$91.72M | -$26.60M | -$243.32M | -$74.28M |
| EPS (Diluted) | -$3.59 | -$0.28 | -$2.86 | -$1.18 |
| Operating cash flow | -$13.25M | -$21.69M | -$369.52M | -$86.10M |
| Free cash flow | n/a | -$21.86M | -$370.18M | -$86.15M |
| Cash & equivalents | $6.17M | $27.14M | $89.67M | $80.88M |
| Total assets | $107.33M | $42.21M | $411.94M | $198.10M |
| Total liabilities | $145.39M | $15.78M | $110.64M | $306.60M |
| Shareholders' equity | -$38.06M | $26.43M | $301.30M | -$108.50M |
| Return on year-end equity | n/a | -100.6% | -80.8% | n/a |
| Shares outstanding | 28.84M | 96.62M | n/a | 56.66M |
Revenue, most recent five fiscal years
| Fiscal year | Celularity Inc | Cue Biopharma, Inc. | Alumis Inc. | Foghorn Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $26.55M Ended 2025-12-31 | $27.47M Ended 2025-12-31 | $24.05M Ended 2025-12-31 | $30.91M Ended 2025-12-31 |
| 1 year earlier | $54.22M Ended 2024-12-31 | $9.29M Ended 2024-12-31 | n/a | $22.60M Ended 2024-12-31 |
| 2 years earlier | $22.77M Ended 2023-12-31 | $5.49M Ended 2023-12-31 | n/a | $34.16M Ended 2023-12-31 |
| 3 years earlier | $17.98M Ended 2022-12-31 | $1.25M Ended 2022-12-31 | n/a | $19.23M Ended 2022-12-31 |
| 4 years earlier | $21.34M Ended 2021-12-31 | $14.94M Ended 2021-12-31 | n/a | $1.32M Ended 2021-12-31 |